Enzymatica AB · OMXSTO:ENZY
Enzymatica AB — Investor Presentation (2021)
32 slides from Enzymatica AB's investor presentation, 2021
Slide 1: Company presentation 2021
Company presentation 2021 Enzymatica AB (publ)
Slide 2: Contents
Contents This is Enzymatica...................................................................................................3 The year in figures...................................................................................................4 Important events during the year....................
Slide 3: This is Enzymatica
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations This is Enzymatica Business concept Enzymatica develops and sells medical devices to treat infection-related diseases in the upper Enzymat
Slide 4: The year in figures
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations The year in figures Sales trend (SEK m) 120 Key figures (SEK thousand) 2021 2020 2019 2018 2017 Net sales, SEK thousand 57,243 111,245 61,
Slide 5: Important events during the year
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations Important events during the year Q1 Q2 Q3 Q4 » Enzymatica restructured the organization » The Japanese Patent Office granted » The Chinese
Slide 6: How Enzymatica was affected by Covid-19
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Operations How Enzymatica was affected by Covid-19 The coronavirus pandemic has had a very strong impact on Enzymatica’s sales and earnings in 2021.
Slide 7: Enzymatica – heading for the future
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Comments from the CEO Enzymatica – heading for the future In less than 15 years, Enzymatica has gone from a creative commercial opportunities for eac
Slide 8: Three reasons to invest in Enzymatica
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Three reasons to invest in Enzymatica Throughout the challenging times of the past two years, Enzymatica continued to work accordi
Slide 9: A scalable business model
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy A scalable business model Flexibility and scalability are hallmarks of the Enzymatica business model. By balancing its own experti
Slide 10: Continued three-dimensional expansion
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Continued three-dimensional expansion For many years, Enzymatica’s growth strategy has been based on three pillars: Strengthening
Slide 11: Strong partners all over the world
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Strong partners all over the world In recent years, Enzymatica has built strong relationships with some of the world’s leading pla
Slide 12: Financial targets for Enzymatica
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Targets & strategy Financial targets for Enzymatica On November 2, 2021, the Board adopted financial targets for Enzymatica. At the end of 2026, the
Slide 13: The share and shareholding
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION The share The share and shareholding At year-end Enzymatica had 8,420 shareholders – a decrease of about 12 percent compared with 2020. The share pri
Slide 14: Number of shareholders
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION The share The share and shareholding Enzymatica’s ten largest shareholders December 30, 2021 Name Number of shares Percentage of capital and votes (%
Slide 15: Share capital and share price
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION The share Share capital and share price Increase in number of Total number Change in Total Registered Transaction shares of shares share capital shar
Slide 16: 16 | Enzymatica company presentation 2021
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION 16 | Enzymatica company presentation 2021
Slide 17: ColdZyme treats the cause of colds
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market ColdZyme treats the cause of colds The ColdZyme® barrier consists of two ingredients that together provide effective protection GLYC
Slide 18: Global market with great potential
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market Global market with great potential The global market for over-the-counter cold and allergy products is estimated at USD 37 billion a
Slide 19: Situation in local markets
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market Situation in local markets ColdZyme was sold at the end of 2021 on 36 markets worldwide, either under its own brand or under the bra
Slide 20: New MDR regulation entails extensive changes
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market New MDR regulation entails extensive changes May 26, 2021 was an historic day for EU medical device legislation. The Medical Device
Slide 21: Global patent portfolio protects rights
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Product & market Global patent portfolio protects rights Enzymatica has extensive patent protection for ColdZyme and continuously works to expand thi
Slide 22: 22 | Enzymatica company presentation 2021
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION 22 | Enzymatica company presentation 2021
Slide 23: Research on barrier technology potential
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Research on barrier technology potential The purpose of research and development at Enzymatica is to investigate the possibi
Slide 24: Building out production for global expansion
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Building out production for global expansion During a year with lower-than-expected demand, the focus has been on expanding
Slide 25: Ongoing efforts to ensure high quality
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Ongoing efforts to ensure high quality Enzymatica’s systematic quality management system encompasses the entire value chain,
Slide 26: Sustainable development with a focus on people
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Production & development Sustainable development with a focus on people Enzymatica shall be a good stakeholder in the community and take responsibili
Slide 27: 27 | Enzymatica company presentation 2021
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION 27 | Enzymatica company presentation 2021
Slide 28: Comments from the Chairman of the Board
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Corporate governance Comments from the Chairman of the Board Foundation laid for expansion There is no doubt that 2021 was a challenging year for We
Slide 29: Corporate governance report
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Corporate governance Corporate governance report Governance of Enzymatica takes place through the General Meeting, the Board of Directors, the CEO an
Slide 30: Corporate governance: Auditor, CEO and senior management
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Corporate governance Auditor General Meeting on October 18, 2021 resolved to approve an Deloitte was re-elected as the company's auditor at the 2021
Slide 31: Financial Overview
CONTENTS OPERATIONS TARGETS & STRATEGY THE SHARE PRODUCT & MARKET PRODUCTION & DEVELOPMENT CORPORATE GOVERNANCE FINANCIAL OVERVIEW CONTACT INFORMATION Financial Overview (SEK thousand) 2021 2020 2019 2018 2017 Net sales, SEK thousand 57,243 111,245 61,306 52,560 59,446 Capitalized development costs,
Slide 32: Enzymatica AB contact details
Enzymatica’s unique barrier technology protects people’s health by creating a shield against viruses, bacteria and other microorganisms that cause colds and infections. We focus on global expansion through innovation and partnerships. ENZYMATICA AB (PUBL) IDEON SCIENCE PARK, SE-223 70 LUND, SWEDEN.